/Alteration Of F-box And Wd Repeat Domain Containing 7 (fbxw7) Gene As A Predictive Biomarker For Treating Cancer With Wee1 Inhibitors
Abstract
The present disclosure provides, among other things, methods for treating cancer comprising administering an effective dose of a WEE1 inhibitor such as Azenosertib, or a pharmaceutically acceptable salt thereof, to a subject selected to have a cancer associated with at least one alteration in the F-box and WD repeat domain containing 7 (FBXW7) gene.
Full Text
What is claimed is:
The present disclosure provides, among other things, methods for treating cancer comprising administering an effective dose of a WEE1 inhibitor such as Azenosertib, or a pharmaceutically acceptable salt thereof, to a subject selected to have a cancer associated with at least one alteration in the F-box and WD repeat domain containing 7 (FBXW7) gene.
Timeline
Filed
05/14/2026Published
09/03/2026Granted
Not AvailableIPC Codes(4)
A61K 31/519:ortho- or peri-condensed with heterocyclic rings
A61K 31/506:not condensed and containing further heterocyclic rings
A61P 35/00:Antineoplastic agents